Catheter Precision Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Catheter Precision Inc (VTAK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Catheter Precision Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs 229,573M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+112.8% annualized vs trailing 12 months), vs accelerating (+3.4%) for its tracked peer group.
- Growth: Catheter Precision Inc generated 380.7% revenue growth year over year in Q2 2026, vs 10.1% for its competitors combined.
- Profitability: Its -324.4% net margin compares with 12.3% for the peer group.
- Scale: Catheter Precision Inc ranks #210 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Catheter Precision Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.11M compares with $0.37M for the peer group (0.3x).
- Structure: Catheter Precision Inc operates in the following segments: Private Aviation, Cardiac Electrophysiology.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
VTAK Sales vs. its Competitors, Q2 2026
Catheter Precision Inc reported revenue growth of 380.66 % year on year in Q2 2026, above its competitors' combined revenue growth of 10.08 %.
With a net margin of -324.44 %, Catheter Precision Inc reported lower profitability than its competitors (12.34 %).
Catheter Precision Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
API endpoints for this dataset
Catheter Precision Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Catheter Precision Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Catheter Precision Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Catheter Precision Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Catheter Precision Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs 380.7% for Catheter Precision Inc. Catheter Precision Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Catheter Precision Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Catheter Precision Inc | - | Yes | Yes | No |
| Competitors combined (33) | ||||
| High-Confidence Competitors (5) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
VTAK Stock Performance relative to its Competitors
VTAK Stock Performance relative to High-Confidence Competitors
VTAK Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adagio Medical Holdings inc | 282.9% | Outperformed |
| 2 | Axogen inc | 282.9% | Outperformed |
| 3 | Atricure Inc | 282.9% | Outperformed |
| 4 | Livanova Plc | 282.9% | Outperformed |
| 5 | Becton Dickinson And Company | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Catheter Precision Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Catheter Precision Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Catheter Precision Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Catheter Precision Inc |
0.18 | 1.91 |
 Thermo Fisher Scientific Inc |
267,724.73 | 47,351.00 |
 Abbott Laboratories |
192,651.69 | 46,585.00 |
 Medtronic Plc |
132,095.43 | 37,542.00 |
 Stryker Corp |
125,308.33 | 26,300.00 |
 Boston Scientific Corporation |
63,917.04 | 21,070.00 |
| SUBTOTAL | 965,502.50 | 230,273.41 |
Sign in to see all competitors of Catheter Precision Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Catheter Precision Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Catheter Precision Inc's Competitors Named by the Company
Competitive relationships identified from Catheter Precision Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Abbott | Company report | 85% |
| Medtronic, Plc. | Company report | 85% |
| Inari Medical | Company report | 85% |
| Boston Scientific Corp. | Company report | 85% |
| Haemonetic | Company report | 85% |
| Biosense-Webster (J&J) | Company report | 85% |
| Strata Skin Sciences Inc | Company report | 85% |
| Penumbra Inc | Company report | 85% |
| Cardiovascular Systems Inc | Company report | 85% |
| Shockwave Medical Inc | Company report | 85% |
| Livanova Plc | Company report | 85% |
| Orchestra Biomed Holdings Inc | Company report | 85% |
| Atricure Inc | Company report | 85% |
| Integra Lifesciences Holdings Corp | Company report | 85% |
| Abiomed Inc | Company report | 85% |
| Cvrx inc | Company report | 85% |
| Meihua International Medical Technologies Co Ltd | Company report | 85% |
| Artivion Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Ir med Inc | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
| Adagio Medical Holdings inc | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
Company report basis, confidence, active dates and source counts for Catheter Precision Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Catheter Precision Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Catheter Precision Inc | Private Aviation 73.50 % |
| Thermo Fisher Scientific Inc | Clinical Research 20.15 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 56.20 % |
| Boston Scientific Corporation | Cardiovascular 66.29 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Catheter Precision Inc .
Catheter Precision Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Catheter Precision Inc | 0 | 112,647 | -775,765 |
| Thermo Fisher Scientific Inc | 267,725 | 378,808 | 56,712 |
| Abbott Laboratories | 192,652 | 405,087 | 47,174 |
| Medtronic Plc | 132,095 | 395,179 | 55,463 |
| Stryker Corp | 125,308 | 469,643 | 64,696 |
| Boston Scientific Corporation | 63,917 | 357,119 | 59,220 |
| PEERS TOTAL | 965,502 | 369,608 | 43,350 |
Sign in to see all peers for Catheter Precision Inc .
Catheter Precision Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Thermo Fisher Scientific Inc | North America 51.63 % |
| Abbott Laboratories | Non-US 57.70 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.92 % |
| Boston Scientific Corporation | United States 64.40 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Catheter Precision Inc .
Catheter Precision Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Catheter Precision Inc's industry classification, broader than the peer set above. Market cap in millions of $.Catheter Precision Inc ranks #210 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 607, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 164,558 | 13.47 % |
| 2 | Medtronic Plc | 132,095 | 10.81 % |
| 3 | Stryker Corp | 125,732 | 10.29 % |
| 4 | 3m Company | 98,540 | 8.06 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Medline Inc | 1,234 | 5.2% |
| 10 | Resmed Inc | 1,234 | 5.2% |
| 210 | Catheter Precision Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Catheter Precision Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Catheter Precision Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 205 | Regentis Biomaterials Ltd | 1 | - |
| 206 | Nu med Plus Inc | 1 | -71.67 % |
| 207 | Bone Biologics Corporation | 1 | -81.88 % |
| 208 | Encision Inc | 0 | -93.45 % |
| 209 | Ir med Inc | 1,234 | 12.3% |
| 210 | Catheter Precision Inc | 0 | - |
| 211 | Nuwellis Inc | 1,234 | 12.3% |
| 212 | Therapeutic Solutions International Inc | 1,234 | 12.3% |
| 213 | Glucotrack Inc | 1,234 | 12.3% |
| 214 | Omnia Wellness Inc | 1,234 | 12.3% |
| 215 | Allurion Technologies Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Catheter Precision Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Catheter Precision Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 47.73 % | 46.20 % (avg) | +1.5 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.66 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 1.10 % | 7.13 % (avg) | -6.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Catheter Precision Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 36.9x | - |
| EV / EBITDA | - | 17.8x | - |
| P/B | 0.0x | 4.6x | -4.6x |
| Return on Equity | -132.48 % | industry aggregate | -144.46 % |
| Return on Invested Capital | -68.52 % | -6.78 % (avg) | -61.74 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Catheter Precision Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | -38.81 % | -99.50 % | - | - | -4.98 % | 95.00 % |
| Operating Margin | -801.92 % | -818.59 % | -133,027.27 % | - | - | - | - |
| Return on Invested Capital | -59.13 % | -62.92 % | -75.95 % | -102.89 % | -130.54 % | -28.85 % | -84.30 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Catheter Precision Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Catheter Precision Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.9% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Catheter Precision Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 607 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.10 % vs industry average 7.13 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Catheter Precision Inc's dedicated Suppliers and Customers pages, not here.
Catheter Precision Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Catheter Precision Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Catheter Precision Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+112.8% annualized vs trailing 12 months).
Weaknesses
- Return on equity 144.5 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Catheter Precision Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Catheter Precision Inc | 0.05 | 0.16 | 0.48 |
| Thermo Fisher Scientific Inc | 0.39 | 1.69 | 0.81 |
| Abbott Laboratories | 0.42 | 1.50 | 0.44 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.50 | 2.08 | 0.65 |
| Boston Scientific Corporation | 0.23 | 1.50 | 0.46 |
Sign in to see all peers for Catheter Precision Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Catheter Precision Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Catheter Precision Inc | Q2 2026 | +380.7 % | - |
| Thermo Fisher Scientific Inc | Q3 2026 | +9.1 % | +6.2 % |
| Abbott Laboratories | Q2 2026 | +13.0 % | -47.8 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q3 2026 | +7.6 % | -12.3 % |
| Boston Scientific Corporation | Q3 2026 | +1.4 % | -23.2 % |
| PEERS TOTAL | +8.7 % | +13.6 % |
Sign in to see all peers for Catheter Precision Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Catheter Precision Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Catheter Precision Inc | Q2 2026 | +6,478.6 % | +114.3 % |
| Thermo Fisher Scientific Inc | Q3 2026 | +133.0 % | +8.2 % |
| Abbott Laboratories | Q2 2026 | +9.7 % | -1.0 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q3 2026 | +3.0 % | +26.7 % |
| Boston Scientific Corporation | Q3 2026 | +12.3 % | -0.6 % |
Sign in to see all peers for Catheter Precision Inc .
Catheter Precision Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Catheter Precision Inc | - | - | - |
| Thermo Fisher Scientific Inc | 6.29% | 7.46% | 13.32% |
| Abbott Laboratories | 5.56% | 6.45% | 10.41% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.66% | 8.63% | 15.61% |
| Boston Scientific Corporation | 7.82% | 9.14% | 13.75% |
Sign in to see all peers for Catheter Precision Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Catheter Precision Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Catheter Precision Inc | - | 0.09 |
| Thermo Fisher Scientific Inc | 38.14 | 5.65 |
| Abbott Laboratories | 35.54 | 4.14 |
| Medtronic Plc | 302.32 | 3.52 |
| Stryker Corp | 34.69 | 4.76 |
| Boston Scientific Corporation | 18.68 | 3.03 |
| PEERS AVERAGE | 35.77 | 4.19 |
Sign in to see all peers for Catheter Precision Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.